Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 4

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

NCT06676280 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 4
Started
2025-07-24
Last updated
2026-07-01

Condition(s) studied

Cardiovascular Diseases

Investigational drug(s) / intervention(s)

Aspirin →High-intensity statin →Guideline-directed statin therapy

Aspirin: Patients will take aspirin 100 mg/day.

High-intensity statin: Statin intensity is defined according to the 2026 ACC/AHA Guideline on the Management of Dyslipidemia

Guideline-directed statin therapy: Statin intensity is defined according to the 2026 ACC/AHA Guideline on the Management of Dyslipidemia

Study summary

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. The subject must be aged between 40 and 75 years. 2. Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography. 3. Patients who have 1 or more CVD risk factors in below; * dyslipidemia or, * diabetes or, * hypertension or, * family history of CVD or, * smoking 4. Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site. Exclusion Criteria: 1. Individuals who have symptomatic coronary artery disease or heart failure. 2. Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), \>50% carotid stenosis or previous carotid endarterectomy or stenting, aortic aneurysm and peripheral artery disease. 3. Patients who have evidence of myocardial ischemia on non-invasive stress test including stress single photon emission CT myocardial perfusion imaging (SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, stress echocardiography, or treadmill test, or on invasive stress test including Fractional flow reserve (FFR) \< 0.80 on invasive coronary angiography (diameter stenosis\>50% without objective evidence of ischemia could be enrolled). 4. Patients at high risk of bleeding: gastrointestinal hemorrhage or peptic ulcer within the previous 6 months; active hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anticoagulant therapy; or has a history of aspirin allergy. 5. Patients with atrial fibrillation and flutter. 6. Patients with severe left ventricular dysfunction (ejection fraction ≤30%) or severe valvular heart disease who experience dyspnea on exertion (The NYHA (New York Heart Association) Functional Classification III-IV). 7. History of allergy or severe adverse reaction to aspirin or statin or ezetimibe. 8. History of myositis or myopathy with active disease in the 180 days prior to study entry. 9. Patients with active liver disease or persistent unexplained serum transaminase elevation. 10. Patients who have significantly abnormal findings which identified violation for safety by investigator on physical examination, blood test and electrocardiogram. 11. History of alcohol or drug abuse. 12. Concurrent medical condition with a life expectancy of less than 1 years. 13. Pregnant and/or lactating women. 14. Patient was unable to provide written informed consent or participate in log-term follow up.

Primary outcome measure(s)

  • Event rate of a composite of atherosclerotic cardiovascular disease event — 3 years
    cardiovascular death; myocardial infarction ; hospitalization for Acute coronary syndrome; stroke; Transient ischaemic attack; peripheral arterial ischemia ;revascularization of coronary, carotid, or peripheral artery ;or death from an undetermined cause

Trial sites (32)

FacilityCityRegionStatus
Hallym University Medical Center Anyang South Korea Not Yet Recruiting
SAM hospital Anyang South Korea Not Yet Recruiting
Sejong General Hospital Bucheon-si South Korea Recruiting
Dong-A University Hospital Busan South Korea Not Yet Recruiting
Haeundae paik hospital, inje university Busan South Korea Recruiting
Inje University Busan Paik Hospital Busan South Korea Recruiting
Gyeongsang National University Changwon Hospital Changwon South Korea Recruiting
Chungbuk National University Hospital Cheonju South Korea Recruiting
Hallym University Chuncheon Sacred Heart Hospital Chuncheon South Korea Not Yet Recruiting
Kangwon National University Hospital Chuncheon South Korea Recruiting
Keimyung University Dongsan Medical Center Daegu South Korea Recruiting
Kyungpook National University Hospital Daegu South Korea Recruiting
Yeungnam University Medical Center Daegu South Korea Not Yet Recruiting
Chungnam National University Hospital Daejeon South Korea Recruiting
The Catholic University of Korea, Daejeon St. Mary's Hosptial Daejeon South Korea Recruiting
GangNeung Asan Hospital Gangneung South Korea Recruiting
Chonnam National University Hospital Gwangju South Korea Recruiting
Incheon St. Mary's Hospital, The Catholic University of Korea Incheon South Korea Not Yet Recruiting
Jeonbuk National University Hospital Jeonju South Korea Recruiting
Kwangju Christian Hospital Kwangju South Korea Not Yet Recruiting
Asan Medical Center Seoul South Korea Recruiting
Hanil General Hospital Seoul South Korea Recruiting
Hanyang University Seoul Hospital Seoul South Korea Recruiting
Kangbuk Samsung Hospital Seoul South Korea Not Yet Recruiting
Korea University Guro Hospital Seoul South Korea Recruiting
Severance Hospital Seoul South Korea Recruiting
The Catholic University of Korea Seoul St. Mary's Hospital Seoul South Korea Not Yet Recruiting
The Catholic University of Korea, Eunpyeong St. Mary's Hospitall Seoul South Korea Recruiting
Seoul National University Bundang hospital Sŏngnam South Korea Recruiting
The Catholic University of Korea, Uijeongbu St. Mary's Hospital Uijeongbu-si South Korea Recruiting
Ulsan University Hospital Ulsan South Korea Recruiting
Yongin Severance Hospital Yŏngin South Korea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06676280 on ClinicalTrials.gov ↗ ← All trials in South Korea